Tisagenlecleucel (Kymriah®) which is licensed for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||19/09/2018|
|Rapid review completed||18/10/2018|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care.|